The Sigma-1 Gene as a Prognostic Marker in Chemotherapy-Treated Breast Cancer-Antagonists' Synergism With Paclitaxel In Vitro.

ABSTRACT:

Background

Treatment benefits of paclitaxel (Px)-based chemotherapy are often offset by dose-limiting side effects. The sigma-1 receptor (Sig1R) is implicated in chemotherapy (ChT)-induced neuropathy but its role in the metastatic potential of breast cancer (BCa) has not been properly explored.

Methods

This work investigated the predictive and prognostic value of Sig1R gene (S1R) expression for pathologic complete response (pCR) and distant relapse-free survival (DRFS) following neoadjuvant ChT (nChT). We further examined the anticancer efficacy of the Sig1R antagonists IPAG and BD1047 in combination with Px in triple-negative breast cancer (TNBC) cell lines.

Results

We report that S1R positively associated with pCR in two patient cohorts. Upregulated gene clusters in

SUBMITTER: Borde P 

PROVIDER: S-EPMC12611308 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature